MeiraGTx (MGTX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
30 Apr, 2026Executive summary
The annual general meeting is scheduled for June 11, 2026, via live webcast, with shareholders able to vote and submit questions online.
Shareholders of record as of April 21, 2026, are entitled to vote on director elections and auditor ratification.
Proxy materials are available online, with options for electronic or paper voting.
Voting matters and shareholder proposals
Shareholders will vote to elect three Class II directors for terms expiring in 2029.
Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
No other known matters are scheduled for a vote, but proxies may be voted on other business if properly presented.
Shareholder proposals for the 2027 meeting must be submitted by December 31, 2026.
Board of directors and corporate governance
The board consists of seven directors divided into three staggered classes, with annual elections for expiring terms.
Five of seven directors are independent under Nasdaq rules; Ellen Hukkelhoven and Alexandria Forbes are not considered independent.
Four standing committees: Audit, Compensation, Nominating and Corporate Governance, and Science and Technology.
Board leadership is separated between an independent Chairman and the CEO.
Director nominations consider integrity, experience, diversity, and shareholder interests.
Latest events from MeiraGTx
- Late-stage pipeline, transformative gene therapies, and strong partnerships drive near-term approvals.MGTX
Corporate presentation - Q2 2026 net income of $160.7M on $321.4M revenue, fueled by licensing, acquisitions, and clinical progress.MGTX
Q2 2026 - Directors and auditor were elected and ratified, with no shareholder questions submitted.MGTX
AGM 2026 - Late-stage gene therapies advance with pivotal xerostomia data, XLRP filings, and major partnerships.MGTX
Jefferies Global Healthcare Conference 2026 - Late-stage pipeline and riboswitch platform drive transformative therapies for major unmet needs.MGTX
Corporate presentation - Regained RPGR rights and late-stage pipeline progress position for near-term commercialization.MGTX
Bank of America Global Healthcare Conference 2026 - Q1 2026 net loss rose to $46.3M; FDA breakthrough, bota-vec deal, and $100M raise drive pipeline.MGTX
Q1 2026 - Director elections and auditor ratification headline the June 2026 annual meeting agenda.MGTX
Proxy filing - Gene therapy restored vision and quality of life in all 11 LCA4 children, with lasting benefit.MGTX
Study Update